NCT03183531 is a clinical trial of C reactive protein in Newborn; Infection, sponsored by Sisli Hamidiye Etfal Training and Research Hospital.

Who is sponsoring NCT03183531?

NCT03183531 is sponsored by Sisli Hamidiye Etfal Training and Research Hospital.

What drugs are being tested in NCT03183531?

Interventions in NCT03183531: C reactive protein.

What condition does NCT03183531 study?

NCT03183531 studies Newborn; Infection, Newborn Sepsis.

Is NCT03183531 still recruiting?

NCT03183531 is currently completed. Last updated 12 June 2017.

Last reviewed 2017-06-12 · How we verify

NCT03183531

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Protocol for Febrile Neonate Management

Completed Last updated 12 June 2017

What this trial tests

trial testing C reactive protein in Newborn; Infection in 328 participants. Completed in 31 March 2016.

Timeline

1 January 2011

Primary endpoint
31 December 2015

31 March 2016

Quick facts

Lead sponsor	Sisli Hamidiye Etfal Training and Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	328
Start date	1 January 2011
Primary completion	31 December 2015
Estimated completion	31 March 2016
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

C reactive protein

Conditions studied

Newborn; Infection — all drugs for Newborn; Infection →
Newborn Sepsis — all drugs for Newborn Sepsis →

Sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Who can join

Adults 1 Day to 28 Days, any sex, with Newborn; Infection or Newborn Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of present study was to evaluate clinical and laboratory characteristics of febrile neonate and describe the incidence of SBI in febrile neonates. Secondarly investigators aimed to test usefulness of major protocols and new protocol in evaluating only febrile neonate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of C reactive protein

Trials testing the same drug.

NCT06593990 — LA Function and Dimensions As Predictors of Disease Activity in RA · not yet recruiting

Other Sisli Hamidiye Etfal Training and Research Hospital trials

Trials by the same sponsor.

NCT07334002 — The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus · NA · not yet recruiting
NCT07321041 — Effect of Delivery Time on Umbilical Cord Blood Gas Parameters in Cesarean Sections Under General and Spinal Anesthesia · recruiting
NCT07476690 — Effect of rESWT Session Frequency on Spasticity and Function Assessed by Sonoelastography in Children With Cerebral Pals · NA · recruiting
NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients · NA · recruiting
NCT07250243 — Turkish Validation and Reliability of the John Hopkins In-Room Independence Scale · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183531 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sisli Hamidiye Etfal Training and Research Hospital
Last refreshed: 12 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing